[vc_row css=”.vc_custom_1517939115140{padding-right: 20px !important;padding-left: 20px !important;background-color: #fbfbfb !important;}”][vc_column][vc_column_text]Published on July 9, 2019
Dr. Douglas Beall explains the use of mesoblastic progenitor cells (MPC) to treat degenerative disc disease. He explains how MPCs are processed and injected into the disc and discusses the results for a phase II trial that used these MPCs for pain reduction and improved function for up to three years. He also discusses the successful VAST trial and the complex biochemical assays that were used.
[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=”.vc_custom_1488298613118{margin-top: -20px !important;}”]
[/vc_column_text][/vc_column][/vc_row]
Leave a Reply
You must be logged in to post a comment.